Polymyalgia Rheumatica Treatment Market By Based on Diagnostic Method (Blood Tests, Imaging Tests), Based on Drug Class (Corticosteroids, Disease-Modifying Anti-Rheumatic Drugs), By Application (Hospitals, Homecare, Specialty Clinics) By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2022-2032
- Published date: Feb 2022
- Report ID: 77467
- Number of Pages: 323
- Format:
- keyboard_arrow_up
Polymyalgia Rheumatica Treatment Market Overview
Polymyalgia Rheumatica (PMR) is an inflammatory condition that produces muscle pain and stiffness in the neck, hips, shoulders, thighs, and arms. Polymyalgia is a phrase derived from the Greek word “myalgia,” which means “muscle pain.” Pain in numerous bodily sections is referred to as polymyalgia. This disorder is more common in adults over the age of 60. Females are more likely than males to develop it, with a 2:1 ratio. The condition develops over a period of time in some individuals, whereas it occurs overnight in others. Giant Cell Arteritis (GCA) is frequently associated with polymyalgia rheumatic. This illness causes the arteries in the head to enlarge, causing impaired vision and headaches.
Although the specific etiology of the disease is unknown, it is thought that interactions between numerous elements such as autoimmunity, genetic predispositions, and viral infections may contribute to this disease’s emergence. Autoimmunity occurs when an individual’s immune cells attack joints and connective tissue, resulting in polymyalgia rheumatica. According to reports, genetic factors enhance the risk of contracting this condition. According to certain studies, people with the HLA-DR4 haplotype had a higher risk of PMR. Furthermore, those of Scandinavian and northern European origin are particularly vulnerable to PMR. Polymyalgia rheumatica is sometimes caused by viral infections. Some viruses, such as the human parainfluenza virus, adenovirus, and parvovirus B19, have been implicated in PMR.
Detailed Segmentation
Based on Diagnostic Method:
- Blood Tests
- Imaging Tests
Based on Drug Class:
- Corticosteroids
- Disease-Modifying Anti-Rheumatic Drugs
- Non-Steroidal Anti-Inflammatory Drugs
Based on Route of Administration:
- Oral
- Parenteral
Based on End-Use:
- Hospitals
- Homecare
- Specialty Clinics
Based on Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Market Dynamics
Drivers for the Global Polymyalgia Rheumatica Treatment Market:
The increased implementation of improved diagnostic technology is fueling the global polymyalgia rheumatica market. Owing to an increase in the number of studies and research on polymyalgia rheumatic symptoms, this market is expected to further develop. Additionally, the use of sophisticated diagnostic technologies to analyze shoulder subacromial and subdeltoid bursitis, hip synovitis, and iliopectineal bursitis to create effective treatments are expected to augment this market’s economic growth.
Restraints Global Polymyalgia Rheumatica Treatment Market:
There are currently no particular tests for the diagnosis of polymyalgia rheumatica, thus clinicians must rely on a mix of history, physical examination, laboratory tests, and imaging studies to determine an accurate diagnosis.
Opportunities for the Global Polymyalgia Rheumatica Treatment Market:
Rapid technical breakthroughs in technologies like Magnetic Resonance Imaging (MRI) are helping to reduce the risk of errors and contribute to a faster and more accurate diagnosis of this condition. Physical therapy is gaining popularity among customers owing to its high effectiveness and the lack of adverse effects.
Trends for the Global Polymyalgia Rheumatica Treatment Market:
Physiotherapies are individualized treatments that aim to alleviate muscle stiffness and enhance muscle strength dependent on the severity of this condition. Therefore, variables are expected to have a large impact on this market revenue growth over the forecast period.
Competitive Landscape
- Apotex Inc.
- Teva Pharmaceutical Industries Ltd.
- GlaxoSmithKline plc.
- Mayo Foundation for Medical Education and Research (MFMER)
- Cleveland Clinic
- Arthritis Foundation
- Healthily
- Physio.co.uk
- Sparrow Health Systems
For the Polymyalgia Rheumatica Treatment Market research study, the following years have been considered to estimate the market size:
Attribute Report Details Historical Years
2016-2020
Base Year
2021
Estimated Year
2022
Short Term Projection Year
2028
Projected Year
2023
Long Term Projection Year
2032
Report Coverage
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
Regional Scope
North America, Europe, Asia-Pacific, South America, Middle East & Africa
Country Scope
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
Polymyalgia Rheumatica Treatment MarketPublished date: Feb 2022add_shopping_cartBuy Now get_appDownload Sample - Apotex Inc.
- Teva Pharmaceutical Industries Ltd. Company Profile
- GlaxoSmithKline plc.
- Mayo Foundation for Medical Education and Research (MFMER)
- Cleveland Clinic
- Arthritis Foundation
- Healthily
- Physio.co.uk
- Sparrow Health Systems
- settingsSettings
Our Clients
Single User
$5,999
$2,999
USD / per unit
save 50% |
Multi User
$7,999
$3,499
USD / per unit
save 55% |
Corporate User
$12,999
$4,499
USD / per unit
save 65% | |
---|---|---|---|
e-Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 2,999) | Buy Now ($ 3,499) | Buy Now ($ 4,499) |